-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pfizer (Pfizer) announced today that the British Medicines and Health Products Administration (MHRA) has approved the oral JAK1 inhibitor Cibinqo (abrocitinib) to be marketed in the UK for the treatment of moderate to severe disease in adults and adolescents over 12 years old who are suitable for systemic therapy.
Atopic dermatitis is a chronic skin disease characterized by skin inflammation and skin barrier defects.
Abrocitinib is an oral JAK1 inhibitor
▲The molecular structure of Abrocitinib (picture source: Edgar181, Public domain, via Wikimedia Commons)
Abrocitinib has achieved positive results in multiple phase 3 clinical trials
In the phase 3 clinical trial called JADE DARE, abrocitinib was statistically superior to the approved antibody therapy in each of the evaluated efficacy indicators
At present, Pfizer has submitted abrocitinib regulatory applications to many countries and regions in the world, including the United States, the European Union, Australia and Japan
Reference materials:
[1] UK's MHRA Grants Marketing Authorisation for Pfizer's CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis.
